Clinical Trial Update: Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Menactra in healthy infants at 9 months and co-administered with Pentacel at 15-18 months; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Meningitis
• Meningococcal Infection
• Pertussis
• Tetanus

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))
• Pentacel (DTaP-Hib-IPV vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Infection | Phase 4 | Status: COMPLETED | Results posted: 2015-12-15